Amarin Corporation plc is a biopharmaceutical company engaged in developing and bringing to market therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and the therapeutic benefits of polyunsaturated fatty acids. The company’s lead product includes Vascepa, a prescription-only omega-3 fatty acid that can be used along with diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. For more information, visit the company’s website at www.amarincorp.com.